Discharge 2012: Innovative Medicines Initiative (IMI)

This procedure concerns the 2012 discharge for the Innovative Medicines Initiative (IMI). Discharge is the final approval of the way the EU budget was implemented by an EU body. It ensures accountability and transparency in the use of public funds.

The European Parliament grants discharge to the IMI's management. This decision affects the accountability of the IMI's financial management and operational performance for the 2012 financial year.